<DOC>
	<DOCNO>NCT01505634</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability add 125 mg 250 mg dos MK-7655 imipenem/cilastatin adult 18 year older complicate urinary tract infection ( cUTI ) . The primary hypothesis MK-7655 + imipenem/cilastatin treatment regimen non-inferior imipenem/cilastatin respect proportion participant favorable microbiological response completion intravenous ( IV ) study therapy .</brief_summary>
	<brief_title>Study Safety , Tolerability , Efficacy MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone Treatment Complicated Urinary Tract Infection ( cUTI ) ( MK-7655-003 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>MK-7655</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Cilastatin</mesh_term>
	<criteria>Clinically suspect and/or bacteriologically document cUTI acute pyelonephritis judge investigator serious ( require hospitalization treatment IV antibiotic therapy ) Pyuria , determine midstream cleancatch ( MSCC ) catheterize ( indwell straight catheter ) urine specimen great equal 10 white blood cell ( WBCs ) per highpower field ( hpf ) standard examination urine sediment great equal 10 WBCs/mm3 unspun urine One positive urine culture within 48 hour enrollment Complete obstruction portion urinary tract ( require permanent indwell urinary catheter instrumentation ) , know ileal loop , intractable vesicoureteral reflux A temporary indwelling urinary catheter place remove study entry . Perinephric intrarenal abscess know suspected prostatitis Uncomplicated UTI Any history recent accidental trauma pelvis urinary tract Any amount effective antibiotic therapy obtain urine culture admission study prior administration first dose IV study therapy An infection treat great 24 hour systemic antibiotic therapy know effective presume documented etiologic pathogen ( ) within 72hour period immediately prior consideration entry study History serious allergy , hypersensitivity ( e.g. , anaphylaxis ) , serious reaction carbapenem antibiotic , cephalosporin , penicillin , beta ( Î² ) lactam agent History serious allergy , hypersensitivity ( e.g. , anaphylaxis ) , serious reaction betalactam inhibitor ( e.g. , tazobactam , sulbactam , clavulanic acid ) History seizure disorder Currently treat valproic acid receive treatment valproic acid 2 week prior screen . Rapidly progressive terminal illness unlikely survive approximately 6 8 week study period Pregnant expect conceive , breast feeding , plan breast feed study A response study therapy ( IV study therapy subsequent oral ciprofloxacin ) within timeframe treatment specify protocol consider unlikely . Concurrent infection would interfere evaluation response study antibiotic Need concomitant systemic antimicrobial agent addition designate various study treatment group ( use vancomycin , daptomycin , linezolid allow certain infection ) cUTI due confirm fungal pathogen Currently receive immunosuppressive therapy , include use highdose corticosteroid Prior recipient renal transplantation Laboratory abnormality specify protocol History illness , opinion investigator , might confound result study pose additional risk administer study drug Currently participate , participate , clinical study involve administration investigational experimental medication ( licensed regulatory agency ) time presentation previous 30 day prior screen anticipate participate clinical study course trial Estimated actual creatinine clearance &lt; 5 mL/minute , currently undergo hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>